Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha)

American Journal of Hematology

Volumn 53, Issue 3, 1996, Pages 169-174

  Steegmann, Juan Luis ^b   Requena, Maria José ^b   Casado, Luis Felipe ^b   Pico, Mónica ^b   Peñarrubia, Maria Jesús ^b   Ferro, Maria Teresa ^a   Resino, Mónica ^a   Fernandez Rañada, Jose María ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Chronic myelogenous leukemia; Cytogenetics; Interferon alpha; M BCR; Southern

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FOLLOW UP; HUMAN; METHODOLOGY; PRIORITY JOURNAL; SOUTHERN BLOTTING;

BIOLOGICAL RESPONSE MODIFIERS; BLOTTING, SOUTHERN; BONE MARROW EXAMINATION; CELL DIVISION; DNA, NEOPLASM; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON ALFA-2A; KARYOTYPING; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; REMISSION INDUCTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 0029910798     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199611)53:3<169::AID-AJH4>3.0.CO;2-X     Document Type: Article

References (28)

1. Clarkson B, Strife A: Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7:1683, 1993.
2. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290, 1973.
3. Talpaz M, Kantarjian H, Kurzrock R, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114: 532, 1991.
4. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 330:820, 1994.
5. Giralt S, Kantarjian H, Talpaz M: The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol 32:152, 1995.
6. Morgan GJ, Wiedemann JM: The clinical application of molecular techniques in Philadelphia-positive leukemia. Br J Haematol 80:1, 1992.
7. Yoffe G, Blick M, Kantarjian H, et al: Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69:961, 1987.
8. Hook EB: Exclusion of chromosomal mosaicism: Tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 29:94, 1977.
9. Higano CS, Raskind WH, Singer JW: Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437, 1992.
10. Ferro MT, del Potro E, Krsnik I, et al: Unusual translocations and other changes in acute leukemia. Cancer Genet Cytogenet 54:163, 1991.
11. Sambrook J, Fritsch EF, Maniatis T: Analysis and Cloning and Eukaryotic Genomic DNA. Isolation of DNA From Mammalian Cells: Protocol I. Anonymous Molecular Cloning. A Laboratory Manual. Ed. 2. New York: Cold Spring Harbor Laboratory Press, 1989, p 16.
12. Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specificity activity. Anal Biochem 132:6, 1983.
13. Steegmann JL, Perez M, Vazquez L, et al: Interferon alpha treatment of accelerated-phase chronic myeloid leukemia in relapse after bone marrow transplantation: A case with complete cytogenetic and molecular remission. Bone Marrow Transplant. 7:65, 1991.
14. Steegmann JL, Díez JL: El interferón alfa y las infusiones de linfocitos de donante en las recaídas de la leucemia mieloide crónica post-TMO. Sangre 40:229, 1995.
15. Blennerhasset GT, Furth ME, Anderson A, et al: Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myeloid leukemia. Leukemia 2:648, 1988.
16. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Br J Haematol 86:76, 1994.
17. Simonsson B, Oberg G, Killander A, et al: Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Stem Cells Dayt 11(Suppl 3):73, 1993.
18. Dhingra K, Kurzrock R, Kantarjian H, et al: Minimal residual disease in interferon-treated chronic myelogenous leukemia: Results and pitfalls of analysis based on polymerase chain reaction. Leukemia 6:754, 1992.
19. Cross NC, Feng L, Chase A, et al: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929, 1993.
20. Kantarjian HM, Talpaz M, Hester J, et al: Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive dose chemotherapy. J Clin Oncol 13:553, 1995.
21. De Maeyer E, De Maeyer-Guignard J: The effects of interferons on cell growth and division. In De Maeyer E (ed): "Interferons and Other Regulatory Cytokines." New York: John Wiley & Sons, 1988, p 134.
22. Ernstoff MS, Kirkwood JM: Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med 76:593, 1984.
23. Wandl UB, Butzler R, Niederle N, et al: Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment. Leukemia 8:776, 1994.
24. Talpaz M, Kantarjian H, Kurzrock R, et al: Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myeloid leukemia. Cancer 69:410, 1991.
25. First International Workshop on chromosomes in Leukemia 1977: Chromosomes in Ph1-positive chronic granulocytic leukemia. Br J Haematol 39:305, 1978.
26. Ayscue LH, Ross DW, Ozer H, et al: Bcr/abl recombinant DNA analysis versus karyotype in the diagnosis and therapeutic monitoring of Chronic Myeloid Leukemia. Am J Clin Pathol 94:404, 1990.
27. Grossman A, Silver RT, Szatroswki TP, et al: Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 5:540, 1991.
28. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, et al: Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 85:2705, 1995.